This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Cerevel Therapeutics Holdings Croissance future
Future contrôle des critères 0/6
Cerevel Therapeutics Holdings is forecast to grow earnings and revenue by 17% and 69.6% per annum respectively while EPS is expected to grow by 22.4% per annum.
Informations clés
17.0%
Taux de croissance des bénéfices
22.4%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 28.8% |
| Taux de croissance des recettes | 69.6% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 02 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?
Apr 30
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 65 | -541 | N/A | -499 | 1 |
| 12/31/2025 | N/A | -548 | N/A | -535 | 1 |
| 12/31/2024 | N/A | -441 | N/A | -386 | 2 |
| 3/31/2024 | N/A | -460 | -371 | -367 | N/A |
| 12/31/2023 | N/A | -433 | -346 | -342 | N/A |
| 9/30/2023 | N/A | -393 | -336 | -332 | N/A |
| 6/30/2023 | N/A | -397 | -343 | -340 | N/A |
| 3/31/2023 | N/A | -388 | -323 | -320 | N/A |
| 12/31/2022 | N/A | -352 | -297 | -293 | N/A |
| 9/30/2022 | N/A | -318 | -263 | -258 | N/A |
| 6/30/2022 | N/A | -280 | -227 | -222 | N/A |
| 3/31/2022 | N/A | -243 | -218 | -210 | N/A |
| 12/31/2021 | N/A | -225 | -189 | -179 | N/A |
| 9/30/2021 | N/A | -196 | -184 | -168 | N/A |
| 6/30/2021 | N/A | -173 | -167 | -144 | N/A |
| 3/31/2021 | N/A | -146 | -146 | -125 | N/A |
| 12/31/2020 | N/A | -148 | -137 | -118 | N/A |
| 9/30/2020 | N/A | -175 | -124 | -112 | N/A |
| 6/30/2020 | N/A | -172 | -116 | -111 | N/A |
| 3/31/2020 | N/A | -151 | -97 | -94 | N/A |
| 12/31/2019 | N/A | -128 | -72 | -71 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: CERE is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: CERE is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: CERE is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: CERE is forecast to have no revenue next year.
Croissance élevée des revenus: CERE is forecast to have no revenue next year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if CERE's Return on Equity is forecast to be high in 3 years time